Formycon Partners with MS Pharma for Keytruda Biosimilar FYB206 Commercialization in MENA Region
核心洞察
Formycon AG and MS Pharma (搜索) have signed an exclusive licensing and supply agreement for FYB206, a biosimilar candidate to Keytruda (pembrolizumab), covering the Middle East and North Africa region.
FYB206 is approaching the end of its clinical development phase, with primary endpoint results expected in the first quarter of 2026.
The partnership aims to improve access to cancer treatment in a region where Keytruda generates approximately $240 million in sales, representing the highest-selling biologic in MENA.
Formycon AG and MS Pharma (搜索) have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to the blockbuster cancer drug Keytruda (pembrolizumab), across the Middle East and North Africa (MENA) region. The partnership includes an option for future technology transfer and represents a significant step toward expanding access to affordable cancer treatment in the region.
Clinical Development Nears Completion
FYB206 is currently approaching the end of its clinical development phase, with Formycon expecting results for the primary endpoint in the first quarter of 2026. This timeline positions the biosimilar for potential regulatory submissions and market entry in the coming years.
"This licensing deal for the MENA region represents the start of the commercial partnering activities for our Keytruda biosimilar candidate," said Nicola Mikulcik, Chief Business Officer of Formycon AG. "Further agreements for additional regions and countries shall follow in due time."
Strategic Partnership Builds on Established Collaboration
The agreement leverages an existing successful partnership between the two companies, which has already been implemented for Formycon's biosimilars FYB201, FYB202, and FYB203. MS Pharma (搜索) brings established local capabilities and an advanced manufacturing facility in Saudi Arabia to support regional distribution.
"Extending our partnership with Formycon for FYB206 (pembrolizumab), is a strategically important milestone for MS Pharma (搜索)," commented Kalle Känd, CEO of MS Pharma. "This collaboration not only strengthens our position as a leader in biosimilars across the MENA region but also demonstrates our commitment to expanding access to innovative cancer therapies."
Significant Market Opportunity
Pembrolizumab, a humanized monoclonal antibody and immune checkpoint inhibitor, is used to treat a variety of tumors. With global sales of $29.5 billion in 2024, Keytruda ranks among the world's best-selling drugs. In the MENA region specifically, estimated sales reached approximately $240 million, positioning it as the highest-selling biologic in the region and highlighting substantial oncology demand and market potential.
Financial Terms and Regional Impact
Under the agreement terms, Formycon will receive an upfront payment and will be eligible for additional payments contingent on achieving certain development and regulatory milestones. The company will also receive a significant share of gross profits generated in the region.
MS Pharma (搜索) operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia, employing over 2,000 people across 12 countries. The company aims to contribute to greater treatment availability while supporting national strategies focused on localization, resilience, and sustainable access to oncology care.
Biosimilar Market Context
The biosimilar market represents a growing opportunity as biopharmaceutical patents expire. By 2032, 45 blockbuster drugs with an estimated total annual global turnover of more than $200 billion will lose patent protection. Global sales of biosimilars currently amount to around $21 billion, with analysts projecting growth to over $74 billion by 2030.
Formycon already has two biosimilars on the market (FYB201/ranibizumab and FYB202/ustekinumab) and another approved by regulatory authorities (FYB203/aflibercept). Four pipeline candidates, including FYB208/dupilumab, are currently in development.